Comparison between Eris Lifesciences IPO and IndiGrid InvIT InvIT.
Eris Lifesciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while IndiGrid InvIT InvIT is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Eris Lifesciences IPO is up to ₹1,740.49 Cr whereas the issue size of the IndiGrid InvIT InvIT is up to ₹2,249.96 Cr. The final issue price of Eris Lifesciences IPO is ₹603.00 per share and of IndiGrid InvIT InvIT is ₹100.00 per share.
| Eris Lifesciences IPO | IndiGrid InvIT InvIT | |
|---|---|---|
| Face Value | ₹1 per share | ₹100 per share |
| Issue Price (Lower) | ₹600.00 per share | ₹98.00 per share |
| Issue Price (Upper) | ₹603.00 per share | ₹100.00 per share |
| Issue Price (Final) | ₹603.00 per share | ₹100.00 per share |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ₹60.00 per share | |
| Market Lot Size | 24 shares | 10205 shares |
| Fresh Issue Size | 0 shares | 22,49,96,373 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹2,249.96 Cr |
| OFS Issue Size | 2,88,75,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹1,740.49 Cr | up to ₹0.00 Cr |
| Issue Size Total | 2,88,75,000 shares | 22,49,96,373 shares |
| Issue Size Total (Amount) | up to ₹1,740.49 Cr | up to ₹2,249.96 Cr |
Eris Lifesciences IPO opens on Jun 16, 2017, while IndiGrid InvIT InvIT opens on May 17, 2017. The closing date of Eris Lifesciences IPO and IndiGrid InvIT InvIT is Jun 20, 2017, and May 19, 2017, respectively.
| Eris Lifesciences IPO | IndiGrid InvIT InvIT | |
|---|---|---|
| Anchor Bid Date | Jun 15, 2017 | May 16, 2017 |
| Issue Open | Jun 16, 2017 | May 17, 2017 |
| Issue Close | Jun 20, 2017 | May 19, 2017 |
| Basis Of Allotment (Tentative) | Jun 23, 2017 | May 16, 2017 |
| Initiation of Refunds (Tentative) | Jun 27, 2017 | |
| Credit of Share (Tentative) | Jun 28, 2017 | |
| Listing date (Tentative) | Jun 29, 2017 | Jun 06, 2017 |
| Anchor Lockin End date 1 | Jul 23, 2017 | Jun 15, 2017 |
| Anchor Lockin End date 2 | Sep 21, 2017 | Aug 14, 2017 |
Eris Lifesciences IPO P/E ratio is , as compared to IndiGrid InvIT InvIT P/E ratio of .
| Eris Lifesciences IPO | IndiGrid InvIT InvIT | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | ||||||
| Promoter Shareholding (Post-Issue) | ||||||
| P/E Ratio | ||||||
| Market Cap | ₹8291.25 Cr. | ₹2702.00 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Eris Lifesciences IPO Retail Individual Investors (RII) are offered 28,72,500 shares while in IndiGrid InvIT InvIT retail investors are offered 28,72,500 shares. Qualified Institutional Buyers (QIB) are offered 86,17,500 shares in Eris Lifesciences IPO and 6,75,02,484 shares in IndiGrid InvIT InvIT.
| Eris Lifesciences IPO | IndiGrid InvIT InvIT | |
|---|---|---|
| Anchor Investor Reservation | 1,29,26,250 shares | 10,12,43,520 shares |
| Market Maker Reservation | 0 shares | |
| QIB | 86,17,500 shares | 6,75,02,484 shares |
| NII | 43,08,750 shares | 5,62,50,369 shares |
| RII | 28,72,500 shares | 0 shares |
| Employee | 1,50,000 shares | 0 shares |
| Others | ||
| Total | 2,88,75,000 shares | 22,49,96,373 shares |
Eris Lifesciences IPO subscribed 3.29x in total, whereas IndiGrid InvIT InvIT subscribed 1.35x.
| Eris Lifesciences IPO | IndiGrid InvIT InvIT | |
|---|---|---|
| QIB (times) | 4.68x | 1.14x |
| NII (times) | 0.45x | |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 3.51x | |
| Employee (times) | 0.86x | |
| Other (times) | 1.60x | |
| Total (times) | 3.29x | 1.35x |
